COVID-19 meets Cystic Fibrosis: for better or worse?

Daniel Peckham (Lead / Corresponding author), Michael F. McDermott, Sinisa Savic, Anil Mehta

    Research output: Contribution to journalArticlepeer-review

    34 Citations (Scopus)


    Cystic fibrosis (CF) is one of the most common autosomal recessive life-limiting conditions affecting Caucasians. The resulting defect in the cystic fibrosis transmembrane conductance regulator protein (CFTR) results in defective chloride and bicarbonate secretion, as well as dysregulation of epithelial sodium channels (ENaC). These changes bring about defective mucociliary clearance, reduced airway surface liquid and an exaggerated proinflammatory response driven, in part, by infection. In this short article we explore the overlap in the pathophysiology of CF and COVID-19 infection and discuss how understanding the interaction between both diseases may shed light on future treatments.

    Original languageEnglish
    Pages (from-to)260-262
    Number of pages3
    JournalGenes and Immunity
    Early online date1 Jul 2020
    Publication statusPublished - 1 Aug 2020


    • Biological sciences
    • Genetics

    ASJC Scopus subject areas

    • Genetics(clinical)
    • Genetics
    • Immunology


    Dive into the research topics of 'COVID-19 meets Cystic Fibrosis: for better or worse?'. Together they form a unique fingerprint.

    Cite this